Meeting
2022 ASCO Annual Meeting
The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
Authors
Nicole N Scheff
UPMC Hillman Cancer Center, Pittsburgh, PA
Nicole N Scheff , Marci Lee Nilsen , Jinhong Li , Alexandria L Harris , Andrew Swartz , Ronan Wenhan Hsieh , Jennifer Lynn Anderson , Robert L. Ferris , Ashley Menk , Greg M Delgoffe , Dan Paul Zandberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6044)
DOI
10.1200/JCO.2022.40.16_suppl.6044
Abstract #
6044
Poster Bd #
36
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2022 ASCO Annual Meeting
Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
First Author: Ye Guo
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris
Poster
2015 ASCO Annual Meeting
Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
First Author: Lillian L. Siu